PatternsRadar
Sign in

ZIMLABZim Laboratories Limited

NSE
147.80INR-1.02 (-0.69%)Close · 20 Nov 2026
4 Nov 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹793 CrMarket cap
382.9P/E (TTM)
30.6%Delivery

Filings & corporate actions

16 results filed
CSV
Next results · Q3 FY27
Expected 29 Jan 2027 – 11 Feb 2027
Estimate: filed 29–42 days after quarter end, last 4 times
2026
  • 4 NovresultsResults · Q2 FY27 · consolidated and standalone+1.9%NSE
  • 12 OctshareholdingShareholding · 30 Sept 2026+1.4%NSE
  • 6 AugresultsResults · Q1 FY27 · consolidated and standalone-2.8%NSE
  • 17 JulshareholdingShareholding · 30 Jun 2026-1.6%NSE
  • 19 MayresultsResults · Q4 FY26 · consolidated and standalone-1.5%NSE
  • 18 AprshareholdingShareholding · 31 Mar 2026+0.5%NSE
  • 17 MarshareholdingShareholding · 13 Mar 2026+9.6%NSE
  • 11 FebresultsResults · Q3 FY26 · consolidated and standalone-2.2%NSE
  • 13 JanshareholdingShareholding · 31 Dec 2025+3.4%NSE

Reaction to results · all yearsrose on day 0 in 4 of 16 CSV

QuarterFiledDay 0+5D+20DRel vol
Q2 FY274 Nov 2026+1.9%+4.9%—1.3×
Q1 FY276 Aug 2026-2.8%-6.6%+9.0%2.0×
Q4 FY2619 May 2026-1.5%+1.5%+13.3%0.7×
Q3 FY2611 Feb 2026-2.2%-7.5%-13.1%1.4×
Q2 FY2612 Nov 2025-4.3%-4.4%-2.3%0.4×
Q1 FY267 Aug 2025-4.5%-10.9%-7.8%0.3×
Q4 FY2521 May 2025+3.4%+0.7%+19.1%1.1×
Q3 FY2510 Feb 2025-5.0%-8.1%-20.8%0.7×
Q2 FY259 Nov 2024-5.9%-8.5%-0.2%0.9×
Q1 FY253 Aug 2024-3.8%-6.0%+4.9%2.4×
Q4 FY2413 May 2024-1.5%-5.9%-13.9%1.1×
Q3 FY2429 Jan 2024-1.2%+1.1%+2.6%0.8×
Q2 FY241 Nov 2023+3.4%+2.5%-0.9%1.9×
Q1 FY2414 Aug 2023-6.5%+2.2%-4.7%1.7×
Q4 FY2319 May 2023-5.0%-4.1%+11.7%2.5×
Q3 FY233 Feb 2023+0.9%-3.7%+1.5%2.1×
Average-2.2%-3.3%-0.1%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q2 FY27

Revenue YoY+18.9%
Profit YoY—
Interest cost YoY+18.3%
Revenue QoQ+12.0%
Profit QoQ—
CAGR2Y3Y4Y5Y6Y7Y
Revenue+3.2%+4.8%————
Profit-64.2%-51.6%————

Key data

Open148.00
Day range147.00 – 153.10
52-week range59.31 – 159.81
From 52w high-7.5%
RSI (14)59.4
ATR (14)8.69
Volume1.37L
Avg volume (20D)1.50L
Rel volume0.91×
Volatility (1Y)48.7%
Turnover₹2.1Cr
Traded value (NSE)₹2.1Cr
VWAP149.81
SMA 50 / 200138.00 / 107.28
Price band20%

Delivery percentage

Latest · 20 Nov 202630.6%
20-day avg48.6%
1-year avg68.4%
Percentile (own history)1st
Range11.7–100.0%
Sessions990

Over the last 20 sessions ZIMLAB settled 48.6% of its traded quantity, which is above average for an NSE equity. Its one-year average is 68.4%, so recent sessions are running 19.7 points lower than usual. The latest session ranks higher than 1% of the 990 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

Dividends, deals & holders

Dividend yield0.00%
Dividend, trailing 12M₹0.00
Paid every year for0 yr
Shareholders13.1K · -10.0% QoQ
Net bulk deals, 30D0.00%
Block deals, 30D₹0
Last bulk buy374 days ago

Performance returns

1D1W1M3M6M1Y
Price-0.69%+4.90%+11.87%+22.15%+47.64%+99.76%

Valuation

Market cap₹793 Cr
Market cap (NSE)₹793 Cr
Free-float cap₹553 Cr
P/E (TTM)382.9
P/E (NSE)385.6
EPS (TTM)0.39
P/B2.7
Net margin (TTM)0.5%
Other income / PBT416.7%
ROE0.8%
Debt / equity0.50
Shares outstanding5.37Cr
Listed25 Nov 2022

Ownership

Promoter30.30%
Promoter Δ QoQ-0.06 pp
Public69.70%
FII0.17%
DII1.19%
Pledged0.00%

Quarterly results · consolidated

Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Revenue (₹ Cr)108.7105.394.2105.4
YoY chg+12.8%-3.2%+31.2%+18.9%
Net profit (₹ Cr)4.43.7(4.0)(2.0)
YoY chg+9.9%-23.4%——
Net margin4.0%3.6%-4.3%-1.9%
EPS0.900.76-0.75-0.38

Shareholding over time

By quarter

30 Sept 2026 · promoter 30.30% · public 69.70%
30 Sept 2022: promoter 33.26%23 Dec 2022: promoter 33.26%31 Dec 2022: promoter 33.26%31 Mar 2023: promoter 33.26%30 Jun 2023: promoter 33.26%30 Sept 2023: promoter 33.26%31 Dec 2023: promoter 33.26%31 Mar 2024: promoter 33.26%30 Jun 2024: promoter 33.26%30 Sept 2024: promoter 33.26%31 Dec 2024: promoter 33.26%31 Mar 2025: promoter 33.26%30 Jun 2025: promoter 33.26%30 Sept 2025: promoter 33.26%31 Dec 2025: promoter 33.26%13 Mar 2026: promoter 30.30%31 Mar 2026: promoter 30.35%30 Jun 2026: promoter 30.36%30 Sept 2026: promoter 30.30%
2022-092026-09
  • Promoter
  • Public and others
Promoter
30.30%
Public
69.70%
Promoter change
-0.06 pp
Filed
12 Oct 2026
FII
0.17%
DII
1.19%
Promoter pledged
0.00%

Who the public is

Mutual funds
1.18%

+0.11 pp QoQ

Insurance
0.00%

0.00 pp QoQ

FPI
0.17%

+0.14 pp QoQ

Retail ≤ ₹2L
13.45%

-0.97 pp QoQ

HNI > ₹2L
17.59%

+0.19 pp QoQ

NRI
2.08%

+0.01 pp QoQ

Bodies corporate
17.89%

+1.04 pp QoQ

Shareholders
13,057

-10.0% QoQ

Major holders

As of 30 Sept 2026
HolderTypeHolding
Anwar Siraj DaudPromoter · Individual25.03%
Elimath Advisors Private LimitedCorporate10.41%
Zakir S ValiIndividual9.41%
Florintree Trinex LlpCorporate8.88%
Investor Education And Protection Fund Authority Ministry Of Corporate AffairsOther3.57%
Sabbah Zulfiquar KamalPromoter · Individual2.80%
Bonanza Business Services Pvt LtdCorporate2.31%
Dr Iguer AbdelmounaimIndividual2.17%
Zulfiquar KamalPromoter · Individual2.08%
Quince Infotech And Leasing Private LimitedCorporate1.27%

Every promoter-group member, and each public holder above 1%, as filed.

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional, pledge and public-breakdown figures come from the filing's XBRL, which most filings before Sep-2021 lack, so they are absent there rather than zero. Changes are against the previous filing.

Price-band hits

Loading…

Sessions the stock closed at the limit of its daily price band, from NSE's end-of-day list. A stock pinned at the band could not trade past it that day.

Bulk & block deals · 11 Nov 2025

CSV
12 of 42 deals
By year
DateDealClientQuantityPriceValue
11 Nov 2025Buy · bulkELIMATH ADVISORS PRIVATE LIMITED38.40L73.47₹28.2Cr
11 Nov 2025Sell · bulkELIZABETH MATHEW38.40L73.45₹28.2Cr
29 Oct 2025Buy · bulkAJIT RAMKARAN SARDA2.65L81.58₹2.2Cr
29 Oct 2025Sell · bulkAJIT RAMKARAN SARDA1.43L82.02₹1.2Cr
24 Oct 2025Sell · bulkMATHEW CYRIAC15.69L68.84₹10.8Cr
24 Oct 2025Buy · bulkELIMATH ADVISORS PRIVATE LIMITED14.97L68.79₹10.3Cr
17 Jul 2025Sell · bulkELIZABETH MATHEW17.94L115.31₹20.7Cr
17 Jul 2025Buy · bulkMATHEW CYRIAC17.94L115.31₹20.7Cr
20 Mar 2025Sell · bulkYUGA STOCKS AND COMMODITIES PRIVATE LIMITED4.77L93.51₹4.5Cr
20 Mar 2025Buy · bulkYUGA STOCKS AND COMMODITIES PRIVATE LIMITED41.9K99.73₹41.7L
19 Mar 2025Sell · bulkELIMATH ADVISORS PRIVATE LIMITED6.44L84.24₹5.4Cr
19 Mar 2025Buy · bulkELIZABETH MATHEW6.44L84.24₹5.4Cr

A bulk deal is a client trading over 0.5% of the company’s shares in a day; a block deal is one large trade in the separate block window. Quantities and prices are as NSE published them, not split-adjusted.

Every stock on this session →

Takeover-code disclosures

Loading…

Filed under SEBI’s takeover regulations when a holding crosses 5% of the company, and again with every 2% it moves after that. Shares and percentages as filed.

Every stock on this session →

Short selling, lending & margin

Loading…

Shares bought on broker margin funding (MTF) and still held at the day’s end, and the amount brokers have lent against them.

Exchange surveillance

20 Nov 2026
  • Price move > 100% in 1 year · since 19 Nov 2026 — One of the criteria NSE’s surveillance watches: price move > 100% in 1 year.
  • High-low range > 150% in 12 months · since 19 Oct 2026 — One of the criteria NSE’s surveillance watches: high-low range > 150% in 12 months.
  • P/E > 50 (4 quarters) · since 8 Apr 2026 — P/E above 50 on the last four quarters’ earnings.

Price band: 20% · not in the F&O ban.

From NSE’s daily surveillance, price-band and position-limit files. A stock enters the F&O ban when open interest passes 95% of its market-wide position limit and leaves it below 80%; until then no new positions can be opened. CSV: measures · band changes.

Every stock on this session →

Financials · quarterly statement

₹ crore, as filed
By year
 Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Revenue from operations96.3117.981.892.196.3108.771.888.7108.7105.394.2105.4
Other income1.11.51.01.31.81.71.52.01.76.21.02.3
Total income97.4119.482.893.598.1110.473.290.8110.4111.495.2107.7
Total expenses90.4108.481.690.592.4102.375.791.1104.3106.5100.7110.5
└ Finance costs1.72.32.92.92.72.93.33.23.43.33.63.9
└ Depreciation3.93.94.95.04.95.34.95.05.05.15.46.5
Profit before tax7.011.01.23.05.78.1(2.4)(0.3)6.04.9(5.6)(2.7)
Tax expense2.22.90.30.61.73.2(0.6)0.11.61.2(1.6)(0.7)
Net profit4.88.10.92.44.04.9(1.9)(0.4)4.43.7(4.0)(2.0)
EPS0.981.660.180.490.821.01-0.38-0.090.900.76-0.75-0.38
Net margin4.97%6.86%1.10%2.58%4.15%4.49%-2.61%-0.48%4.05%3.55%-4.27%-1.94%
PBT margin7.28%9.33%1.51%3.22%5.92%7.46%-3.39%-0.39%5.56%4.69%-5.92%-2.60%
Tax rate31.79%26.49%27.23%19.63%29.86%39.76%——27.27%24.32%——

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. The balance sheet and cash flow arrive only with the half-year and annual filings, and are in their own section below. Latest filed 4 Nov 2026.

Balance sheet & cash flow · half-yearly

₹ crore, as filed
By year

Balance sheet

 FY23H1 FY24FY24H1 FY25FY25H1 FY26FY26H1 FY27
Total assets341.6365.7446.8427.4472.0470.1539.4547.8
Current assets190.9189.6227.6191.6231.3223.9275.8249.7
└ Cash & equivalents6.414.89.65.11.93.925.16.0
└ Other bank balances1.12.40.90.70.50.718.316.6
└ Current investments0.00.00.00.00.00.00.00.0
└ Trade receivables95.268.4100.281.6106.9102.1109.0101.4
└ Inventories53.766.181.367.986.595.693.885.2
Total equity200.3226.0238.7242.8252.2251.3296.2292.4
└ Attributable to owners200.3226.0238.7242.8252.2251.3296.2292.4
└ Non-controlling interest0.00.00.00.00.00.00.00.0
└ Share capital48.748.748.748.748.748.753.553.7
Borrowings59.660.1106.497.4112.2117.3123.0146.2
└ Current34.922.270.857.371.970.681.483.4
└ Non-current24.637.935.640.140.346.741.662.8
Trade payables58.252.362.447.769.561.672.965.1
Current liabilities110.896.1159.4130.5166.4160.3190.4181.8
Total liabilities141.2139.7208.1184.6219.8218.8243.2255.4
Net debt52.042.995.991.5109.7112.779.6123.6
Debt / equity0.300.270.450.400.440.470.420.50
Current ratio1.721.971.431.471.391.401.451.37

Cash flow, year to date

 FY23H1 FY24FY24H1 FY25FY25H1 FY26FY26H1 FY27
Operating cash flow37.523.216.336.841.219.949.51.3
└ Capex(36.7)(32.4)(73.9)(24.6)(40.8)(15.9)(44.4)(26.6)
Free cash flow0.9(9.2)(57.6)12.20.44.05.1(25.3)
Investing cash flow(36.2)(33.1)(73.0)(24.7)(39.9)(15.6)(56.3)(34.1)
Financing cash flow0.518.259.5(16.7)(9.1)(3.4)28.214.2
└ Dividends paid0.00.00.00.00.00.00.00.0
└ Buybacks0.00.00.00.00.00.00.00.0
Net change in cash1.98.42.8(4.5)(7.7)0.921.4(19.1)

From the half-year and annual results filings: the balance sheet from September 2022, the cash flow from September 2020. Those are when NSE’s XBRL began to carry each statement; earlier filings have it only in the attached PDF. Cash flow columns are year to date, so an H1 column covers April to September and an FY column the full year. Outflows are in parentheses. Net debt is borrowings less cash, bank balances and current investments; for banks, NBFCs and insurers it, debt to equity and the current ratio are left blank because their statements are not built that way.

Announcements & board meetings

Loading…

As the company filed them with NSE, newest first. Board meetings are dated by the meeting, which is usually a week or more after the intimation.

Every stock on this session →

ZIMLAB at a glance

  • ZIMLAB closed at ₹147.8 on 20 Nov 2026, -0.69% on the day, +99.8% over one year, 7.5% below its 52-week high of ₹159.81.
  • Delivery was 30.6% of traded quantity on 20 Nov 2026, the 1st percentile of its own 990 sessions with a reading (20-session average 48.6%, 1-year average 68.4%).
  • Market capitalisation is ₹793 crore at a trailing P/E of 382.9 (trailing EPS ₹0.39).
  • Q2 FY27 results (consolidated, filed 4 Nov 2026): revenue ₹105 crore (+18.9% year on year), net profit ₹-2 crore; the price moved +1.9% on the first session after.
  • Promoters held 30.30% at 30 Sept 2026, down 0.06 percentage points on the previous filing.
  • Q3 FY27 results are expected between 29 Jan 2027 and 11 Feb 2027, going by past filing dates — an estimate, not an announcement.

About

Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE518E01015
SeriesEQ
Listed25 Nov 2022
NSE market cap · 17 Nov 2026₹730 Cr
Free-float market cap (NSE)₹338 Cr
Shares outstanding (NSE)5.37Cr
History from25 Nov 2022
Sessions990

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 20 Nov 2026.